Imunon, Inc. — Director's Dealing 2020

Jun 16, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celsion CORP (CLSN)
CIK: 0000749647
Period of Report: 2020-06-15

Reporting Person: Hooper Robert W (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-15	Option to Purchase Celsion Corporation Common Stock	$3.66	A	4000	Acquired	2030-06-15	Celsion Corporation Common Stock (4000)	Direct
2020-06-15	Option to Purchase Celsion Corporation Common Stock	$2.22	D	70000	Disposed	2028-05-15	Celsion Corporation Common Stock (70000)	Direct
2020-06-15	Option to Purchase Celsion Corporation Common Stock	$2.58	A	70000	Acquired	2028-05-15	Celsion Corporation Common Stock (70000)	Direct

Footnotes

F1: Represents the closing price of Celsion Corporation Common Stock on the date of grant.

F2: The options vest as follows: 1/3 on the one year anniversary of the date of grant; 1/3 on the second year anniversary of the date of grant; and 1/3 on the third year anniversary of the date of grant.

F3: The transaction reported herein reflects a one-time stock option repricing that became effective on June 15, 2020 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the settlement agreement as filed as Exhibit 10.2 on Form 8K dated June 16, 2020, the per share exercise price of the Employee Stock Option (right to buy) has been amended to increase such per share exercise price from $2.22 to $2.58. There have been no other changes to the terms of the Employee Stock Option (right to buy).